Abiopharma

🔍 Palleiko Benjamin L (Executive)

Company: KalVista Pharmaceuticals, Inc. (KALV)

Report Date: 2026-03-06

Detailed Transactions and Holdings:

• Acquired 15,625 shares of Common Stock (Direct)
  Date: 2026-03-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 458,508.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 6,693 shares of Common Stock at $16.0814 per share (Direct)
  Date: 2026-03-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 451,815.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 15,625 shares of Restricted Stock Unit (Derivative)
  Date: 2026-03-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 125,001.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
• F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.08 to $16.4102 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on June 6, 2024, subject to continued service through each vesting date.